Omega Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 97.43 million compared to USD 102.7 million a year ago. Basic loss per share from continuing operations was USD 1.8 compared to USD 2.14 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.065 USD | +3.25% | +5.10% | -31.56% |
May. 30 | Omega Therapeutics, Inc. Announces Termination of Yan Moore as Chief Medical Officer | CI |
May. 29 | Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.56% | 110M | |
+48.09% | 57.87B | |
+41.65% | 40.25B | |
-7.20% | 39.94B | |
-5.96% | 28.54B | |
+12.36% | 26.4B | |
-20.40% | 19.33B | |
+30.03% | 12.4B | |
-0.88% | 12.23B | |
+24.00% | 12.2B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023